Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19

Jason Neidleman, Xiaoyu Luo, Ashley F. George, Matthew McGregor, Junkai Yang, Cassandra Yun, Victoria Murray, Gurjot Gill, Warner C. Greene, Joshua Vasquez, Sulggi Lee, Eliver Ghosn, Kara Lynch, Nadia R. Roan
doi: https://doi.org/10.1101/2021.01.22.21250054
Jason Neidleman
1Gladstone Institutes, San Francisco, CA, USA
2Department of Urology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyu Luo
1Gladstone Institutes, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley F. George
1Gladstone Institutes, San Francisco, CA, USA
2Department of Urology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew McGregor
1Gladstone Institutes, San Francisco, CA, USA
2Department of Urology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junkai Yang
3Department of Medicine, Lowance Center for Human Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cassandra Yun
4Department of Laboratory Medicine, University of California, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Murray
5Zuckerberg San Francisco General Hospital and the University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gurjot Gill
5Zuckerberg San Francisco General Hospital and the University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Warner C. Greene
1Gladstone Institutes, San Francisco, CA, USA
6Department of Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Vasquez
6Department of Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sulggi Lee
5Zuckerberg San Francisco General Hospital and the University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliver Ghosn
3Department of Medicine, Lowance Center for Human Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA
7Department of Pediatrics, Lowance Center for Human Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nadia.roan@gladstone.ucsf.edu kara.lynch@ucsf.edu eliver.ghosn@emory.edu
Kara Lynch
4Department of Laboratory Medicine, University of California, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nadia.roan@gladstone.ucsf.edu kara.lynch@ucsf.edu eliver.ghosn@emory.edu
Nadia R. Roan
1Gladstone Institutes, San Francisco, CA, USA
2Department of Urology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nadia.roan@gladstone.ucsf.edu kara.lynch@ucsf.edu eliver.ghosn@emory.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

SUMMARY

Although T cells are likely players in SARS-CoV-2 immunity, little is known about the phenotypic features of SARS-CoV-2-specific T cells associated with recovery from severe COVID-19. We analyzed T cells from longitudinal specimens of 34 COVID-19 patients with severities ranging from mild (outpatient) to critical culminating in death. Relative to patients that succumbed, individuals that recovered from severe COVID-19 harbored elevated and increasing numbers of SARS-CoV-2-specific T cells capable of homeostatic proliferation. In contrast, fatal COVID-19 displayed elevated numbers of SARS-CoV-2-specific regulatory T cells and a time-dependent escalation in activated bystander CXCR4+ T cells. Together with the demonstration of increased proportions of inflammatory CXCR4+ T cells in the lungs of severe COVID-19 patients, these results support a model whereby lung-homing T cells activated through bystander effects contribute to immunopathology, while a robust, non-suppressive SARS-CoV-2-specific T cell response limits pathogenesis and promotes recovery from severe COVID-19.

Figure
  • Download figure
  • Open in new tab

HIGHLIGHTS

  • Dysfunctional spike-specific T cells are characteristic of severe COVID-19

  • Spike-specific CD127+ Th1 cells are increased in survivors of severe COVID-19

  • Spike-specific Tregs and IL6+ CD8+ T cells are increased in fatal COVID-19

  • Escalation of activated lung-homing CXCR4+ T cells associates with fatal COVID-19

BRIEF SUMMARY By conducting CyTOF on total and SARS-CoV-2-specific T cells from longitudinal specimens spanning the entire spectrum of COVID-19 diseases, Neidleman et al. demonstrate that spike-specific Th1 cells capable of IL7-dependent homeostatic proliferation predict survival from severe COVID-19, while Tregs and IL6+ CD8+ T cells recognizing spike predict fatal outcome. Fatal COVID-19 is characterized by escalating activation of bystander CXCR4+ T cells in the lungs. Boosting SARS-CoV-2-specific CD4+ T effector responses while diminishing CXCR4-mediated homing may help recovery from severe disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Van Auken Private Foundation and David Henke (N.R.R.); the Program for Breakthrough Biomedical Research (N.R.R., E.G., S.L., J.V., which is partly funded by the Sandler Foundation; philanthropic funds donated to Gladstone Institutes by The Roddenberry Foundation and individual donors devoted to COVID-19 research (N.R.R.); Awards #2164 (N.R.R.), #2208 (N.R.R.), and #2160 (to S.L.) from Fast Grants, a part of Emergent Ventures at the Mercatus Center, George Mason University; and NIH R01 AI123126-05S1 (E.G.). We acknowledge the NIH DRC Center Grant P30 DK063720 and the S10 1S10OD018040-01 for use of the CyTOF instrument.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the University of California, San Francisco (UCSF) Human Research Protection Program (HRPP). The institutional review board (IRB) approval number is IRB # 20-30588.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# Lead contact

Data Availability

Datasets are available through the following link: https://doi.org/10.7272/Q67H1GTB

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 28, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19
Jason Neidleman, Xiaoyu Luo, Ashley F. George, Matthew McGregor, Junkai Yang, Cassandra Yun, Victoria Murray, Gurjot Gill, Warner C. Greene, Joshua Vasquez, Sulggi Lee, Eliver Ghosn, Kara Lynch, Nadia R. Roan
medRxiv 2021.01.22.21250054; doi: https://doi.org/10.1101/2021.01.22.21250054
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19
Jason Neidleman, Xiaoyu Luo, Ashley F. George, Matthew McGregor, Junkai Yang, Cassandra Yun, Victoria Murray, Gurjot Gill, Warner C. Greene, Joshua Vasquez, Sulggi Lee, Eliver Ghosn, Kara Lynch, Nadia R. Roan
medRxiv 2021.01.22.21250054; doi: https://doi.org/10.1101/2021.01.22.21250054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8792)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10570)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1758)
  • Nursing (103)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (220)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3989)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)